X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Markets 2002: Reflections... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jan 4, 2003

    Markets 2002: Reflections...

    The year 2002 saw both the BSE Sensex and the NSE Nifty gain a little over 3% YoY. The performance doesn't seem too enthusing, but it was hardly surprising considering a sluggish economy, below expectation monsoons and 3% GDP forecast by the CMIE. But the Indian indices did perform better than the leading global indices, for whom 2002 was largely disappointing.

    Bucking the trend...
      Index as on
    Dec 31,2001
    Index as on
    Dec 31,2002
    %
    CHANGE
    BSE-SENSEX 3,262 3,377 3.5%
    S&P CNX NFTY 1,059 1,094 3.3%
    Dow 10,022 8,342 -16.8%
    NASDAQ 1,950 1,336 -31.5%
    FTSE 5,217 3,940 -24.5%
    DAX 5,160 2,893 -43.9%
    Nikkei 10,543 8,579 -18.6%
    Hang Seng 11,397 9,321 -18.2%
    Shanghai Composite 1,646 1,358 -17.5%

    We analysed the components of NSE Nifty to get a bearing of what happened in India Inc. during 2002. Out of the 50 stocks that make up the Nifty, 18 finished in the red during 2002. The top 25 gainers list included 3 banks, 3 auto, 3 software, 3 cement, 2 pharma, 2 engineering, 1 hotel and 1 steel company. The divestment probables, i.e. PSUs too were the key movers (3 in all).

    PSUs: Some of the biggest gainers in 2002 belonged to the divestment group. Shipping Corporation emerged as the No.1 gainer (up 116%) during the year. HPCL followed closely with a gain of 108%. The news of BPCL not making it to the divestment slot saw the stock price recede, but it still managed to finish 2002 with 14% gains. One can deduce that PSUs were hot in 2002 and going by the mood of investors, it is likely to see a premium position in 2003 too.

    Software: The year also saw the return of software during the second half. Digital, Satyam and Infosys represented the sector in the Nifty, but their gains were not even close to yesteryear’s multi-bagger performance. Satyam topped the 3, with 18% gains. While 2001 saw Wipro bag a huge US$ 70 m contract from the telecom subsidiary, Lattice Group, UK – the biggest outsourcing deal ever for an Indian company, 2002 followed it up with Wipro and TCS bagging US$ 50 m – US$ 70 m per year deal with Lehman Brothers. In another landmark development, Satyam tied up with Computer Services Corporation, (CSC). This was perhaps for the first time that an Indian IT services company tied up with a competitor in the west. The move was significant in the sense that CSC would be able offer its services at a very competitive rate by outsourcing the work to Satyam. Satyam on the other hand, will be able to leverage on CSC’s brand and strong presence in the markets like US and Europe. Though the contract started on a smaller scale, it opened a door of possibilities for others in the sector.

    Banks: 2002 was also a landmark year for the Indian banking sector. The year saw passing of the NPA ordinance bill, speeding up of restructuring and technology orientation in the sector. Retail was the ‘mantra’ for the industry and consumers saw finance available at never before rates. Housing and vehicle demand was healthy in a year of slipping IIP growth thanks largely to affordable finance. ICICI Bank, SBI and Oriental Bank were among the top gainers. ICICI Bank saw its first year of merged operations (with ICICI) and SBI’s restructuring and retail success caught the investor’s fancy. In 2003, investors will be keenly watching the NPA recovery moves as well as the M&A activities in the sector. The year seems ripe for a host of partnerships and strategic stake sales in the sector.

    Auto: The year saw the comeback of Telco as commercial vehicle demand picked up and its passenger car division recorded profits for the first time in the September quarter. Restructuring moves by M&M through stake sales in non-core businesses and the launch of the SUV ‘Scorpio’ saw this company too, emerge as a key gainer. Though Hero Honda displaced Bajaj Auto from the Numero Uno slot in the two wheeler segment, the latter’s impressive portfolio restructuring in favour of motorcycles saw the company’s fortunes rise as it grew faster in this segment than Hero Honda itself. Bajaj saw its motorcycle volumes rise by over 50% YoY in the period April-September 2002. And the trend continues.

    Nifty Top 10 gainers
    COMPANY PRICE ON
    Dec 31,2001 (Rs)
    PRICE ON
    Jan 1, 2003 (Rs)
    %
    CHANGE
    52-WEEK
    H/L
    BSE-SENSEX 3,262 3,394 4.0% 3,758 / 2,828
    S&P CNX NFTY 1,059 1,096 3.5% 1,206 / 920
    SHIP. CORP. 30 65 115.9% 112 / 29
    HPCL 139 289 108.1% 345 / 134
    TATA STEEL 87 151 73.7% 152 / 85
    TELCO 100 162 62.1% 173 / 97
    ICICI BANK 89 141 59.2% 164 / 85
    SBI 182 283 56.1% 319 / 176
    IPCL 52 80 52.0% 158 / 51
    ORIENTAL BK. 33 50 49.1% 53 / 32
    TATA CHEM 40 58 47.0% 70 / 39
    RANBAXY 432 597 38.4% 611 / 421
    More Gainers...

    Cement: Out of the top 4 cement companies, 3 figured in the top 25 list. ACC, L&T and Grasim gained in a year that saw despatches show healthy growth at 10-15% for these companies. The consolidation in the sector, with ACC-Guj Ambuja and L&T-Grasim combine seemed imminent. The year also saw Grasim ruffle Sebi feathers over its open offer for hiking stake in L&T. The L&T management too, was up in arms against the move. This issue is likely to continue figuring in headlines during 2003.

    Pharma: 2002 was a year, which saw both success and failure in equal measure for domestic pharma companies. While Ranbaxy basked under the glory of milestone payments from Bayer over Cipro XR 500, Dr. Reddy’s received a major setback with suspension of clinical trials for the outlicenced anti-diabetic molecule, Ragaglitazar. However, both the companies ended 2002 with hope and optimism. The US courts ruled in favour of Dr. Reddy’s in the Amlodiphine Malate patent. Consequently, the company will be able to launch the product by August 2003, when Pfizer's exclusivity term on the product expires. Similarly, Ranbaxy received US FDA approval to commercialise Isotretinoin capsules, an equivalent of ‘Accutane’ that has a market of US$ 23 m in the US. So while Ranbaxy occupied its spot among gainers, Cipla and Dr. Reddy’s finished in the red during 2002. The new year is full of promises for the Indian pharma companies, with a host of generic filings and product pipelines to be put to test.

    And finally, though index heavyweight Reliance ended the year in red, the group’s interest in IPCL and BSES saw both these companies finish among the top. During the year, Reliance made an open offer for management control of BSES and saw through an impressive restructuring at IPCL.

    The losers...

    FMCG: The year was disappointing for FMCG companies as poor monsoon overhang and economic sluggishness continued. The year saw tough times for oral care and malted beverage companies. Though soaps and detergents recorded decent demand, topline sales of FMCG major, HLL, witnessed an unprecedented decline for the first time in many years. For the first nine months of 2002, HLL reported an over 8% topline dip. Consequently, the stock lost over 18% market cap during the year. With rural economy showing little signs of picking up, the index heavyweight is looking at another tough year ahead. But the company that was the worst hit in the sector was GSK Consumer (formerly SmithKline Beecham Consumer Healthcare). The stock lost 34% of its value as the malted beverage market shrunk. The company being the market leader (65% share with Horlicks and Boost) was the worst hit, reporting 7% dip in topline growth in the first nine months of 2002.

    In all, 6 FMCG companies lost value among the Nifty losers. The others were Dabur, Colgate, Britannia and ITC. Colgate’s inability to expand the oral care market, ITC’s diversifications and Britannia’s dairy business demerger were the key factors for this poor show. The year also saw Cadbury bidding adieu to the Indian investor as it opted to delist from the bourses. Reckitt Benckiser may be the next in line in 2003.

    Telecom: Though the telecom sector was a boon to the consumers in 2002, it proved to be a deathblow for traditional monopolies like MTNL and VSNL. With ISD charges seeing over 40% fall, and its market share being eaten up rapidly by competition led by Bharti, VSNL saw its profits pruned by over 30% in the September quarter. MTNL’s performance was similar. If Bharti proved to be the nemesis of MTNL and VSNL in 2002, Reliance Telecomm may give Bharti a run for its money in 2003. The company is rolling out WiLL (limited mobility) during this year and its competitive rates have already forced all cellular operators to announce a significant cut in mobile STD tariffs. And this is just the beginning. Tata Power too, suffered in 2002 owing to investors concern over its significant exposure to group telecom companies, Tata Teleservices and VSNL.

    Nifty Top 10 losers
    COMPANY PRICE ON
    Dec 31,2001 (Rs)
    PRICE ON
    Jan 1, 2003 (Rs)
    %
    CHANGE
    52-WEEK
    H/L
    BSE-SENSEX 3,262 3,394 4.0% 3,758 / 2,828
    S&P CNX NFTY 1,059 1,097 3.5% 1,206 / 920
    VSNL 206 99 -52.30% 235 / 88
    DABUR 68 44 -35.50% 70 / 43
    SB CONS. 396 262 -33.90% 411 / 248
    HCL TECHNOLOGIES 276 188 -31.80% 330 / 153
    MTNL 126 95 -24.40% 178 / 90
    CIPLA 1,134 898 -20.80% 1,209 / 806
    COLGATE 167 135 -19.20% 171 / 123
    HLL 223 182 -18.40% 266 / 152
    NIIT 227 187 -17.40% 347 / 107
    BRITANNIA 610 511 -16.20% 630 / 481
    More Losers...

    Among the other key losers was Gujarat Ambuja, which lost 14% market cap owing to concerns over triggering of an open offer to ACC shareholders at a significant premium, owing to Sebi’s investigation.

    With the government likely to miss its fiscal deficit target once again and expectations of a populist budget this year, thinks do not look too strong on the reform agenda. Also, concerns over US – Iraq tussle continue to drive crude prices higher, which is likely to water down to the Indian economy going forward. Demand prospects for the FMCG sector look challenging owing to the sluggish agricultural output. While everyone is expectant of a revival in 2003, investor opinion is divided sharply as to which sector will lead the turnaround, if at all. In a recent poll on Equitymaster, we asked users ‘Which sector will outperform in 2003?’ giving them a choice between TMT, PSUs and pharma. 31% of respondents favoured TMT, 40% favoured PSUs and 29% voted for pharma sector.

    2003 in a sense is a ‘Year of Reckoning’, both in terms of measuring the government’s seriousness on reforms and in terms of expectations of an economic revival. By the look of it, divestment, Reliance’s performance in the telecom sector, growth in HLL’s topline, consolidation in cement and banking sector and order flow for the tech companies will be the key pointers for the index movements this year.

     

     

    Equitymaster requests your view! Post a comment on "Markets 2002: Reflections...". Click here!

      
     

    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    You've Heard of Timeless Books... Ever Heard of Timeless Stocks? (The 5 Minute Wrapup)

    Aug 19, 2017

    Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.

    Why NOW Is the WORST Time for Index Investing (The 5 Minute Wrapup)

    Aug 18, 2017

    Buying the index now will hardly help make money in stocks even in ten years.

    Trump Takes a Beating (Vivek Kaul's Diary)

    Aug 18, 2017

    Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.

    How To Read Your Mutual Fund Account Statement Correctly (Outside View)

    Aug 17, 2017

    PersonalFN simplifies the mutual fund account statement for you.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE SENSEX


    Aug 18, 2017 (Close)

    MARKET STATS